Your EOB shows CO-50 again. Or CO-197. Or B15. If you're seeing the same denial codes week after week, the problem isn't bad luck — it's a workflow gap you haven't plugged yet. Here's what each code means and the specific fix.
Disclaimer: This is educational, not billing, legal, or medical advice. Payer policies change frequently and your situation may differ from the examples here. Always verify current requirements with your payer's most recent published policy and consult qualified billing or compliance professionals. Use this information at your own risk.
Denial 1: CO-50 — Medical Necessity Not Established
CO-50 is the most common denial in specialty and genetic testing billing. The payer received your claim but decided the clinical information doesn't support coverage under their policy.
The fix: This is almost always a documentation problem, not a clinical one. The ordering physician's notes may clearly support the service — but if you didn't include the specific diagnosis codes, the NCCN category reference, or the clinical history that matches the payer's policy criteria, the reviewer can't make the connection.
Pull the payer's medical policy for the test or drug. Find the coverage criteria. File your appeal with a letter of medical necessity that addresses each criterion by name. Attach the NCCN guideline pages. Don't restate the clinical situation — map the patient to the criteria.
For oncology and genetic testing, request a peer-to-peer review immediately after a CO-50 denial. This is your highest-yield move. Most payers allow 5–14 business days from denial to make that request.
Denial 2: CO-197 — Prior Authorization Not Obtained
CO-197 means the service was delivered but the payer says no PA was on file. You're either dealing with a retro-auth situation or a documentation failure.
The fix: First, verify your records. If PA was obtained, provide the authorization number and approval date in your appeal. This resolves faster than almost any other denial type.
If PA genuinely wasn't obtained before service, file for retro-authorization immediately. Most payers allow retro-auth for emergent or urgent clinical situations with documentation explaining why pre-service authorization wasn't feasible. For an oncology patient where biopsy results came back requiring immediate treatment decisions, that's a documented clinical urgency. For a scheduled test where someone forgot to submit, your options are narrower.
Watch your contract. Some provider agreements specify timely filing windows and retro-auth eligibility. Know the payer's window before you wait a week to file.
Denial 3: CO-16 — Claim Lacks Required Information
CO-16 is a catch-all for missing or invalid data fields. Payers aren't required to tell you exactly what's missing, though many will indicate it in the remark code (look for N codes on the EOB).
The fix: Cross-reference the claim against the payer's submission requirements. Common missing elements: referring provider NPI when required, DEX Z-code for MolDX-managed tests, place of service code mismatch, missing taxonomy code, or an ICD-10 code truncated to 3 characters when 5 are required.
For genetic testing specifically, if you're billing a Medicare patient and the test is managed by Palmetto GBA under MolDX, missing the DEX Z-code in the appropriate field is an instant CO-16. Get the Z-code assigned through MolDX before billing.
Denial 4: CO-A1 — Experimental or Investigational
CO-A1 or similar E&I denial codes mean the payer has classified the test or treatment as not meeting their evidentiary threshold for coverage.
The fix: This requires the most work of any denial type. You need to build an evidentiary case:
- FDA clearance or approval for the specific indication (include 510(k) number or PMA number)
- NCCN guideline listing with category designation (Category 1 or 2A is your best argument)
- Peer-reviewed publications demonstrating clinical utility — not just technical performance
- Positive coverage determinations from other payers or CMS (NCD or LCD)
- Any payer-specific exception criteria for E&I services (some plans cover E&I services when standard therapy has failed)
For laboratory-developed tests that haven't completed a MolDX technical assessment, getting through that process and obtaining a DEX Z-code and positive coverage determination can change the clinical evidence landscape for commercial payer appeals.
Denial 5: CO-4 — Procedure Code Inconsistent with Modifier
This one is almost always a coding error. The modifier you billed (26, TC, 59, 91, etc.) doesn't logically apply to the procedure code on the claim.
The fix: Have your coding team review the modifier combination. Modifier 59 (distinct procedural service) is commonly over-applied to molecular testing codes — it's appropriate when the same code is billed more than once on the same day for different specimens or distinct indications, but it needs documentation to support it. Modifier 91 (repeat clinical diagnostic laboratory test) is the right modifier for repeat testing of the same analyte, but payers require documentation that the repeat was clinically necessary and not a duplicate.
Correct the modifier, add documentation if required, and resubmit.
Denial 6: B15 — Payment Denied Because Your Claim Was Not Filed on Time
B15 or timely filing denials happen when the claim doesn't reach the payer within the contractual or regulatory filing window. Most commercial plans have 12-month timely filing windows. Medicare Part B has a 12-month window from date of service.
The fix: There isn't much to do if you genuinely filed late — timely filing denials are the hardest to overturn. Your appeal needs documentation proving the claim was submitted on time (fax confirmation, portal submission record, EDI transaction log). If you can show submission within the window, the denial gets reversed. If you can't, you're arguing for a hardship exception, which payers rarely grant.
The real fix is upstream: implement timely filing tracking in your billing system and set automated alerts at 60, 90, and 180 days from service date.
Denial 7: OA-23 — Payment Adjusted Because This Service or Item Denied When Billed as Separate Service
OA-23 typically means the payer considers your service to be bundled into another code billed on the same claim or in the same episode.
The fix: Check the NCCI edits (National Correct Coding Initiative) for the code pair. CMS publishes NCCI tables; most clearinghouses surface these as edit warnings before submission. If the bundling is incorrect — services were truly separate and non-overlapping — appeal with documentation of the distinct clinical purpose of each service. If the NCCI edit is valid, you may need to unbundle, correct the codes, or apply appropriate modifiers.
For molecular testing, this comes up when billing multiple CPT codes from the same code family on the same specimen. Payers sometimes bundle these; your appeal needs to articulate why each code represents a distinct test with a distinct result.
Sources
- HCPCS Level II code set and CMS NCCI (National Correct Coding Initiative) — CMS.gov
- AMA CPT Code Set — current edition
- 42 CFR §405.978 (Medicare redetermination process)
- 45 CFR §147.136 (internal claims and appeals — ACA-compliant plans)
- Palmetto GBA / MolDX program — DEX Z-code requirements